Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs SAR 156597 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms ESTAIR
- Sponsors Sanofi
- 29 Jan 2018 This trial has been completed in Greece.
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 This trial has been completed in Denmark.